Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. reported that executive vice president, general counsel and secretary Jonathan P. Graham acquired 10,723 shares of Amgen common stock on March 3, 2026 through a grant or award, at a stated price of $0.0000 per share.
After this award, Graham directly holds 44,478 shares of Amgen common stock. The total includes 590 dividend equivalents credited under Amgen’s equity incentive plan, which will pay out in shares on a one-to-one basis as the related restricted stock units vest.
Gordon Murdo reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon received a grant of 13,403 shares of Amgen common stock as an equity award, with no cash paid per share. After this grant, he directly holds 56,807 shares. The total includes 740 dividend equivalents credited to his unvested restricted stock units, which will be paid in shares on a one-to-one basis according to their vesting schedule.
Bradway Robert A reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc.'s Chairman, CEO and President Robert A. Bradway reported an equity award of 42,657 shares of common stock on March 3, 2026. The shares were granted at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this grant, his direct ownership increased to 457,146 common shares, which include 2,414 dividend equivalents credited to unvested RSUs under Amgen’s equity incentive plan. The filing also shows indirect holdings of 90,000 shares held by a GRAT and 90,000 shares held by a spousal GRAT.
Amgen Inc. reported that VP, Finance & CAO Matthew C. Busch acquired 938 shares of common stock on March 3, 2026 through a grant or award, at a stated price of $0.00 per share. After this equity award, his directly held common stock position increased to 4,361 shares.
The reported holdings include 60 dividend equivalents (DEs) granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan. These DEs are credited to Busch’s unvested restricted stock units and will be paid out in Amgen common shares on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Amgen EVP of Operations Esteban Santos exercised stock options and sold shares. On February 26, 2026, he exercised nonqualified stock options for 30,501 and 24,291 shares of Amgen common stock at exercise prices of $162.6000 and $177.4600 per share, respectively, and received common stock through derivative exercises.
On the same date, he sold 30,501 and 24,291 shares of common stock in open-market transactions at an average price of $379.1173 per share, for total sales of 54,792 shares, including shares sold to cover the option exercise price and required withholding taxes. After these transactions, he directly owned 76,618 shares and held an additional 903.8036 shares indirectly through the company’s 401(k) plan.
Amgen reports a Form 144 notice to sell 54,792 common shares. The filing lists two equity compensation grants as the sources: 05/01/2017 grant for 24,291 shares and 04/27/2018 grant for 30,501 shares. The proposed transactions are described as cash sales and dated 02/26/2026.
Amgen Inc. notified Nasdaq of the voluntary withdrawal of the 2.000% Senior Notes due 2026 from listing and registration. Nasdaq Stock Market LLC certified it has complied with applicable rules under 17 CFR 240.12d2-2 and the issuer has followed the Exchange's withdrawal requirements.
Amgen Inc. vice president sells a small block of shares. Matthew C. Busch, Amgen's VP, Finance & CAO, reported an open-market sale of 1,000 shares of Amgen common stock at a price of $375.79 per share. After this transaction, he directly holds 3,423 shares of Amgen common stock.
The filing notes that these holdings include 60 dividend equivalents granted under Amgen's equity incentive plan. These dividend equivalents are tied to unvested restricted stock units and will be paid out in Amgen shares on a one-to-one basis as those awards vest.
Amgen Inc. issued and sold four series of senior unsecured notes, receiving net proceeds of $3,961,495,000 from the offering. These notes were issued under an existing shelf registration and an indenture originally dated May 22, 2014.
The company sold $1,000,000,000 of 4.200% Senior Notes due 2031, $1,750,000,000 of 4.850% Senior Notes due 2036, $500,000,000 of 5.500% Senior Notes due 2046 and $750,000,000 of 5.650% Senior Notes due 2056. Interest is payable in cash semi-annually on February 19 and August 19, beginning August 19, 2026.
The notes rank equally with Amgen’s other existing and future senior unsecured debt, are senior to subordinated debt, are effectively subordinated to subsidiary obligations and are subordinated to secured obligations to the extent of pledged assets. Upon a defined change of control triggering event, holders may require Amgen to repurchase their notes at 101% of principal plus accrued interest.
Fidelity Brokerage Services LLC filed a Form 144 notice regarding proposed sales of common stock related to prior stock awards for AMGN. The excerpt lists individual stock-award entries with award dates and share counts, including awards of 11/08/2023 (464 shares) and 05/05/2025 (115 shares). The filing lists the broker as Fidelity Brokerage Services LLC and references NASDAQ.